SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Benny Leonard — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBenny Leonard
Date of birth1896-04-07
IdentifiersMRN HR-BX008-SYN-TD; SSN (made up) 000-08-4106
Document date1946-05-26
AuthorMiriam Okafor-Rosenthal, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review on the day of the cardiology consultation. [S]

History of Present Illness

Mr. Leonard returns two weeks after intake and was seen this morning by Dr. Achebe-Lindqvist of cardiology, who did an echocardiogram, an exercise stress echocardiogram and a coronary calcium scan. The echocardiogram showed thickening of the heart muscle from high blood pressure with a normal pumping function, and the stress test showed no sign of narrowed arteries; his breathlessness at peak exercise came with a very high blood pressure rise. The calcium score was 186. He has taken losartan-hydrochlorothiazide each morning, and his home readings over the past week averaged 146/92 mmHg. He has refereed only short undercards, as advised, and has had no chest tightness on those nights. He is relieved that his license is not at risk and worried about the cost of another medicine. [S]

ElementDetail
Home blood pressureAverage 146/92 mmHg over seven days
EchocardiogramConcentric hypertrophy, septum 13 mm, mass index 118 g/m2, ejection fraction 62%
Stress echocardiogramAbout 10.5 METs; no ischemia; peak blood pressure 226/98 mmHg
Coronary calcium scoreAgatston 186, about the 80th percentile
Kidney functionCreatinine 1.04 mg/dL, potassium 4.0 mmol/L two weeks after starting treatment

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest tightness on undercard nights; no palpitations, fainting, orthopnea or ankle swelling
RespiratoryPositiveBreathless only at peak effort on the treadmill this morning
ConstitutionalNegativeNo lightheadedness or tiredness on the new tablet
PsychiatricPositiveWorry about money and work, less than at intake

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morningOne tablet each morningOral route1946-05-12 to 1946-06-30completedS
Atorvastatin 40 mg tablet, one each eveningOne tablet each eveningOral route1946-05-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1946-05-26Body height165cmS
1946-05-26Body weight74.4kgS
1946-05-26Body mass index (BMI) [Ratio]27.3kg/m2S
1946-05-26Systolic blood pressure148mm[Hg]S
1946-05-26Diastolic blood pressure92mm[Hg]S
1946-05-26Heart rate74/minS
1946-05-26Respiratory rate16/minS
1946-05-26Body temperature36.6CelS
1946-05-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1946-05-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-146 mmol/LNormalS
1946-05-26Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.3 mmol/LNormalS
1946-05-26Urea nitrogen [Mass/volume] in Serum or Plasma16mg/dL7-25 mg/dLNormalS
1946-05-26Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.7-1.3 mg/dLNormalS
1946-05-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1941)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1946-05-26Glucose [Mass/volume] in Serum or Plasma94mg/dL65-99 mg/dLNormalS
1946-05-26Left ventricular Ejection fraction62%52-72%NormalS
1946-05-26Interventricular septum Thickness during diastole by US13mm6-10 mmHighS
1946-05-26Left ventricular Myocardial mass/Body surface area [Mass/Area] by US 2D118g/m249-115 g/m2HighS
1946-05-26Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area36mL/m216-34 mL/m²HighS

Physical Exam

Vital signs recorded on 1946-05-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 148/92 mmHg, pulse 74
CardiovascularRegular rhythm; sustained apex beat; fourth heart sound; no murmur at rest or with Valsalva; no edema
RespiratoryClear

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease.
Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to followresolvedconfirmed I10S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation.
Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathyactiveconfirmed I11.9S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart.
Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiographyactiveconfirmed I25.10S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed.
Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetesactiveconfirmed E78.00S — Synthetic diagnosis at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationClinic blood pressure, average of two seated readingsEvery visitCompleted today148/92 mmHg
Self-managementHome blood pressure monitoring (validated upper-arm cuff), readings sent weeklyEvery day during titration; then a week before each visitCompleted todaySeven-day average 146/92 mmHg; above the target of 130/80
LaboratoryBasic metabolic panel (sodium, potassium, creatinine, eGFR)Two to four weeks after starting or changing an ARB or diuretic; then every six monthsCompleted todayTwo weeks after starting losartan-hydrochlorothiazide: sodium 139, potassium 4.0 mmol/L, creatinine 1.04 mg/dL, eGFR 87
LaboratoryUrine albumin-to-creatinine ratioAt diagnosis, then yearlyUp to date22 mg/g at intake, normal
LaboratoryHbA1cAt diagnosis, then yearlyUp to date5.5% at intake
LaboratoryALT before a statinOnce before starting a statinUp to date24 U/L at intake
LaboratoryLipid panelFour to twelve weeks after starting a statin; then yearlyUp to dateLDL 160 mg/dL at intake; recheck eight to twelve weeks after today's start
Imaging12-lead ECGAt diagnosis; then as clinically indicatedUp to dateIntake ECG: left ventricular hypertrophy by voltage, QTc 418 ms
ImagingEchocardiogramAt diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regressionCompleted todayEjection fraction 62%, septum 13 mm, mass index 118 g/m2, left atrial volume index 36 mL/m2; no outflow obstruction
ImagingStress testing or coronary imagingFor new or changed exertional symptoms; not for routine surveillanceCompleted todayExercise stress echocardiogram for exertional symptoms: no inducible ischemia; coronary calcium score 186
ExaminationSymptoms: exertional chest discomfort, breathlessness, palpitations, faintingEvery visitCompleted todayNo chest tightness on undercard nights
ExaminationWeight, BMI and physical activityEvery visitCompleted today74.4 kg, BMI 27.3; walking more
Medication safetyAdherence and side effects (cough, edema, muscle aches, lightheadedness)Every visitCompleted todayTakes the tablet each morning; no lightheadedness or cough
Self-managementReturn to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venueBefore return to full exertion; then every visitCompleted todayUndercards only until home blood pressure is below 140/90; plan given in writing
Self-managementSick-day rulesWhen starting an ARB or diureticCompleted todayHold the tablet on a day of vomiting, diarrhea or inability to drink, and call
Medication safetyAspirin decisionWhen risk changesDeferredNot started while blood pressure is uncontrolled; to be revisited once it is controlled
ReferralCardiology consultationAt intakeCompleted todaySeen by Dr. Achebe-Lindqvist today

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026)

Follow-up: Home readings weekly by phone. Seven-week review at the end of June with a basic metabolic panel; lipid panel at eight to twelve weeks. Next scheduled visit 1946-06-30: seven-week review: home blood pressure, the first weeks back at full cards, symptoms, and a dose increase. [S]